7,549.94

+173.08

+2.35%

52,389.75

+1,104.02

+2.15%

25,253.14

+673.74

+2.74%

2,840.81

+86.71

+3.15%

4.8640

+0.0050

+0.10%

19.92

-5.72

-22.31%

4,131.60

+17.10

+0.42%

74,939.84

-209.13

-0.28%

Crude Oil Dec 26

86.57

-0.28

-0.32%

US Private Equity

10,772.76

+11.86

+0.11%

NasdaqCM - Delayed Quote USD

NeuroOne Medical Technologies Corporation (NMTC)

0.8852 +0.0062 (+0.71%)

At close: November 9 at 4:00:00 PM EST

Loading Chart for NMTC

Chart Range Bar

Interval:

In partnership with ChartIQ

NeuroOne Featured in New York Post on OneRF® Patient’s Remarkable Journey to Overcome Debilitating Facial Pain

NeuroOne Featured in New York Post on OneRF® Patient’s Remarkable Journey to Overcome Debilitating Facial Pain

NeuroOne Secures First Pharmaceutical Industry Purchase Order for StereoCED™ Drug Delivery Platform to Support Tier 1 Global Pharmaceutical Company's Research Program

NeuroOne Secures First Pharmaceutical Industry Purchase Order for StereoCED™ Drug Delivery Platform to Support Tier 1 Global Pharmaceutical Company's Research Program

NeuroOne® Joins Dartmouth-Led Research Team on $1 Million NIH Grant to Advance Neurotransmitter Sensing Technology

NeuroOne® Joins Dartmouth-Led Research Team on $1 Million NIH Grant to Advance Neurotransmitter Sensing Technology

NeuroOne Reports Preliminary Fiscal Q4 Product Revenue Growth of 38.4%; Secures Record $4.5 Million Purchase Order

NeuroOne Reports Preliminary Fiscal Q4 Product Revenue Growth of 38.4%; Secures Record $4.5 Million Purchase Order

NeuroOne Announces Successful Robotic-Assisted Drug Delivery Using Next-Generation StereoCED(TM) Platform

NeuroOne Announces Successful Robotic-Assisted Drug Delivery Using Next-Generation StereoCED(TM) Platform

NeuroOne (NMTC) Q3 2026 Earnings Call Transcript

NeuroOne (NMTC) Q3 2026 Earnings Call Transcript

NeuroOne Medical Technologies Corp (NMTC) (Q3 2026) Earnings Call Highlights: Revenue Grows 16% ...

NeuroOne Medical Technologies Corp (NMTC) (Q3 2026) Earnings Call Highlights: Revenue Grows 16% ...

NeuroOne(R) to Report Third Quarter Fiscal Year 2026 Financial Results on Thursday, August 13, 2026, at 8:30 a.m. Eastern Time

NeuroOne(R) to Report Third Quarter Fiscal Year 2026 Financial Results on Thursday, August 13, 2026, at 8:30 a.m. Eastern Time

NeuroOne(R) Highlights Potential Paradigm Shift for Patients Treated With the OneRF(R) Brain Ablation System Based on Reports by Physicians

NeuroOne(R) Highlights Potential Paradigm Shift for Patients Treated With the OneRF(R) Brain Ablation System Based on Reports by Physicians

NeuroOne(R) Expands Drug Delivery Program Through Collaboration on Pediatric Brain Cancer Clinical Trial

NeuroOne(R) Expands Drug Delivery Program Through Collaboration on Pediatric Brain Cancer Clinical Trial

NeuroOne(R) Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NeuroOne(R) Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mobilize your Website

View Site in Mobile | Classic

Share by: